BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
James Webb Space Telescope finds strongest evidence yet for atmosphere around rocky exoplanet: 'It's really like a wet lava ball' - 2Vote in favor of your Favored Travel Movement
- 3Living Abroad: Social Inundation and Self-improvement
- 4Extraordinary Picks for Home Apparatuses: Making Life Simpler
- 57 Popular Vacation destinations In China
- Ten Awesome Authentic Realities That Will Leave You Interested
- 6 Exceptionally Appraised Summer Travel Objections
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- The moon and sun figure big in the new year's lineup of cosmic wonders
- Dinosaur collagen used to create one-of-a-kind handbag
- Ukraine confirms defence and energy ministers at second attempt
- A definitive Burger Confrontation: Which One Rules?
- New York to require social media platforms to display mental health warnings
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
